Subject index to volumes 14–18

Subject Index to Volumes 14-18

A,AN, and NN patterns in AML, 14:73 in CLL, 18:307 in leukemias, 14:282; 18:4; 18:307 Acquired immunodeficiency syndrome (AIDS) ALL in, 16:341 Burkitt's type ALL with t(8;14), 16:341 chromosome aberrations in male homosexuals, 18:337 partial T-cell expression in ALL, 16:341 14q+ in Haitian patient with Burkitt's lymphoma, 17:283 Acute eosinophilic leukemia, terminating multiple myeloma, 16:81 Acute leukemia adult T-cell, 15:65 childhood ALL, 15:47 chromosome banding in, 14:275 efficacy of cytogenetic methods, 18:1 methods for bone marrow chromosome examination, 18:1 near-tetraploidy in, 14:45 novel 4qllq, 16:245 SCE in lymphocytes of patients, 15:169 t(4;11), 16:21,245 t(11;19) in child with acute T-cell leukemia, 15:181 5 q - , 17:189 12p in, 15:309 14qll in adult T-cell leukemia, 17:279 Acute lymphocytic (lymphoblastic) leukemia (ALL) Burkitt's type with t(8;14), 16:341 chromosomes in childhood ALL, 15:47 differential between Ph + ALL and blast crisis of Ph+ CML, 18:49 hypodiploidy, 16:137 hypotetraploid, 18:179 in AIDS, 16:341 in Down's syndrome, 15:109 karyotypic and clinical findings, 17:165 leukocyte concentration for optimal metaphase yield, 17:75 near-tetraploidy in, 14:45 near-triploidy in Ph+ case, 18:113

novel 4qllq, 16:245 partial T-cell expression in Burkitt's, 16:341 Philadelphia chromosome in, 14:11; 18:173 Philadelphia chromosome and interruption of lambda light chain gene, 18:173 Philadelphia-positive ALL, 14:11; 18:49, 173 prognostic index of chromosome #1, 15:303 SCE frequency in a case with Down's syndrome, 15:109 SCE in lymphocytes of patients, 15:169 significance of cytogenetic findings of erythroid colonies of a Ph + ALL, 18:49 T-cell with Ph, 16:297 variant Ph chromosome in, 14:11 t(1;19), 17:79 t(4;11), 16:21,245 t(4;11;17) in ALL, 17:81 t(10;19), 16:369 1 3 q - in, 18:235 Acute monoblastic leukemia; see also Acute monocytic leukemia chromosome changes, 16:95 t(2;11), 16:95 t(11;17) in, 17:83 Acute monocytic leukemia (AMoL) chromosome changes in, 14:281; 16:95 congenital with t(X;10), 16:357 t(2;11), 16:95 Acute myeloblastic leukemia (AML) chromosome changes in, 14:73,281 colony forming cells, 14:267 hypotetraploid, 18:179 isochromosome X, 15:137 near-tetraploidy in, 14:45 noninvolvement of #16 with fragile sites, 17:1 premature centromere separation, 16:109 SCE in CFU-S, 14:267 variant translocation t(8;21;15) 15:191 t(3;5) in 16:279 t(6;8),inv(9), 18:105

361

362 (A M L ) - - c o n t ' d .

t(6;8) and t(8;21) with chromosome #9 changes in AML, 18:105 t(8;21) in, 14:45 t(8;21),del(9), 18:105 t(8;21;15), 15:191 1 3 q - , 18:235,243 - Y , 17:269 Acute myelomonocytic leukemia (AMML); see also Acute nonlymphocytic leukemia 1 3 q - in, 18:243 1 6 q - without eosinophilia, 18:351 Acute nonlymphocytic leukemia (ANLL); see also AML, APL, and AMML chromosome changes in, 14:275 chromosome changes in APL, 14:247 chromosome #16, 14:275; 17:359 double minute in ANLL, 18:333 efficacy of various cytogenetic methods, 18:1 eosinophilia and chromosome #16, 14:185; 17:359 hypodiploidy and double minute, 18:333 inv(16) in ANLL, 14:185; 17:359 methods of chromosome analysis, 18:1 optimal leukocyte concentration for metaphase yield, 17:75 SCE in lymphocytes of patients, 15:169 structural changes of #10, 16:361 t(3;5) in, 16:279 t(4;11), 16:21 t(6;9) in ANLL, 18:303 5 q - , 17:189 12p in, 15:309 1 2 p - and 19q+ following Alkeran therapy, 15:95 1 3 q - , 18:235,243 - Y , 17:269 Acute phase of CML; see also Blast crisis, t(1;7) in, 18:199, 207 Acute promyelocytic leukemia (APL) atypical with t(15;17), 18:315 complex translocations in, 14:247; 16:45; 17:61 cytogenetic studies in, 14:247; 16:45 t(1;5;15;17) in, 14:247 t(1;8), 16:349 t(15;17) in 14:247 t(X;15;17), 16:45 ultrastructural studies in, 14:247 variant translocation (8;17), 17:61 12p in, 15:309 Adenocarcinoma, lung, cell line karyotype, 15:335 Adenomatosis, of colon and rectum, effects of mutagen on fibroblasts of patients, 17:333

Subject Index Adult T-cell leukemia cell cycle in, 15:65 chromosomes in, 15:65; 17:279 in Japanese, 17:279 PHA-stimulated lymphocytes in, 15:65 SCE in, 15:65 14q11, 17:279 Age and karyotype in AML, 14:73 and sex in AML, 14:73 Agnogenic myeloid metaplasia; see also Myeloproliferative disorders, 1 3 q in, 18:235 Alkeran (L-phenylalanine mustard) chromosome changes, 15:95 preleukemia and leukemia, 15:95 Amplified sequences or genes in HSR of melanoma, 14:131 in melanoma cell ine, 14:131 NOR and centromeric in melanoma, 14:131 rRNA in K562 cell line, 18:27 Animal cancer in tamarins (colon), 14:83 mouse myeloid leukemia, 14:125 mouse thymic lymphoma, 14:303 Ataxia-telangiectasia chromosomal radiosensitivity, 14:163 fibroblasts of, 14:163 heterozygotes, 14:163 t(2;14) in B cells, 18:159 t(19;19), 18:159 translocations, 18:159 Banding G-bands in leukemic cells, 15:373 of chromosomes, 14:275 B-cell cell cycle of tymphocytes of leukemia, 17:181 CLL, 18:307 prolymphocytic leukemia, 14:191 bcr in CML, in "masked" Ph, 18:95 Bladder cancer, cytogenetics, 15:253; 16:259, 289 cancer, technical aspects for chromosome analysis, 16:259 chromosome analysis, 16:259, 289 chromosomes #1 and #11 in, 15:253; 16:289 derivative #11, 16:289 Blast crisis cell kinetics in, 14:111 cytogenetics of, 14:111,293; 15:17; 16:235; 17:21 distinct cell lines, 17:21 iso(17) in, 15:17 karyotype evolution, 14:111; 17:21 lymphoid, 16:235

Subject Index

near-triploidy in P h + CML, 18:113 of P h + CML vs. Ph+ ALL, 18:49 predictive value of cytogenetics, 14:293 relapse and cell lines, 17:21 5 q - in, 16:365 Bloom's syndrome incidence and origin of dicentrics, 15:293 inhibition of SCE with cycloheximide, 17:43 radiation sensitivity of lymphocytes, 16:131 SCE, 17:43 somatic crossing over in erythrocytes, 15:237 Bone marrow chromosomes in ALL, 14:11, 45 chromosomes in AML, 14:45, 73 chromosomes in CML, 14:3, 23, 61,111, 179, 313; 15:17, 47; 18:215 efficacy of various cytogenetic methods, 18:1 in adult T-cell leukemia, 15:65 in mouse myeloid leukemia, 14:125 methods for chromosome analysis, 18:1 NOR activity in CML, 16:311 premature separation of centromeres in AML, 16:109 SCE in myelodysplastic disorders, 15:151 5 q - , 17:189 1 6 q - without eosinophilia, 18:351 Bone marrow transplantation, 12p in recurring leukemia, 15:309 Book review, Catalogue of Chromosome Aberrations in Cancer (F. Mitelman), 14:373 Brain tumors glioblastoma cell line with nearhaploidy, 18:141 glioblastoma cell line with - 1 3 , 17:257 Breast cancer, C-bands in lymphocytes of patients, 18:37 cancer, diploid cell growth, 16:49 cancer in male, 15:113 chromosome changes in effusions, 16:33 chromosomes and cancer, 16:49 cytogenetic analysis in cancer in male, 15:113 Burkitt's lymphoma abnormalities of chromosomes #2 and #8, 16:283 ALL in AIDS, 16:341 ALL with partial T-cell expression, 16:341 chromosome changes in ALL, 16:341 cytogenetic studies in, 14:339 nonendemic, 16:283

363 Spanish cases of, 14:339 t(2;8) in, 14:339 t(8;14) in, 14:339; 16:341 t(8;14) in patient with Waldenstrom's macroglobulinemia, 18:155 6 q - in, 15:169 14q+ in Haitian with AIDS, 17:283 Cancer and chromosome #6, 18:163 and fragile sites, 14:369; 17:1; 16:81 and oncogenes, 14:347 diploid cells in breast cancer, 16:49 effusions, chromosome changes, 16:33 endometrial, 18:283 genes, 16:13 hereditary nonpolyposis colorectal in Navajo family, 15:209 in Turner's syndrome, 16:335 multiple cancers, chromosome damage and SCE, 17:35 of bladder, 15:253; 16:289 of breast, 16:33 of cervix, 16:269 of cervix (SCE in lymphocytes of patients), 14:67; 16:1 of colon in tamarins, 14:83 of kidney, 14:197 of large bowel, C-bands, 14:235 of lung (cell line), 15:335; 16:33 of ovary, 14:147, 153; 16:33, 65 of pancreas, heterogeneity, 14:285; 16:33 of prostate, 16:301 of stomach, 16:33 of testes, 15:375 patient lymphocyte susceptibility to mutagens vs. normals, 17:307 polymorphism of #1, 18:325 von Hippel-Landau disease and, 16:13 6 q - in, 18:183 Carcinogenesis, nucleolar changes in first steps of hepatocarcinogenesis in rat, 17:151 C-bands or chromatin, in lymphocytes of breast cancer patients, 18:37 in lymphocytes of patients with colon and rectal cancer, 14:235 in neoplasia, 14:31 in patients with CNS tumors, 15:129 of chromosome #1,#6, and #9 in children with malignant disease, 16:169 of chromosome #1,#9, and #16, 18:37 of fibroblasts in patients with adenomatosis of colon and rectum, 18:31 af normal lymphocytes, 18:31

364 Carcinogenesis--cont'd. variation in instability of marker chromosomes in tumor, 15:283 Cell cycle and unusual SCD, 15:85 in adult T-cell leukemia, 15:65 in A-T cells, 14:163 in cells of melanoma patients, 15:37 in CML, 14:111 in lymphocytes of Down's syndrome with ALL, 15:109 in patients with hereditary polyposis coli, 16:73 progression of CFU-S of AML, 14:267 progression of lymphocytes of cervix cancer patients, 14:67 progression of stimulated leukemic B cells, 17:181 Cell line choriocarcinoma, 16:251 colon cancer line (COLO 205), 18:251 erythroleukemia (K562), 18:159 gene amplification for dihydrofolatereductase in human cell line, 17:289 glioblastoma with near-haploidy, 18:141 glioblastoma with - 13, 17:257 HeLa, double minutes in, 18:43 hepatitis B virus integration site, 18:19 human hepatoma, karyotype, 18:11, 19 human leukemic line (K562), 17:55 human melanoma line (MeWo), 14:131 human T-cell (CCRF-CEM), karyotype, 14:89 karyotypic changes in rat cell line, 15:243 nude mice, growth of glioblastoma cell line, 18:141 of lung cancer, 15:335 of lymphoma, 14:205 of ovarian cancer, 14:153 oncogene mobility in a human leukemic line, 17:133 rat epithelial, karyotype, 15:243 rRNA in K562 cell line, 17:113; 18:27 short-term culture of mouse lymphoma, 14:303 transplantable giant cell glioblastoma, 18:141 Cell surface markers and cytogenetic changes in lymphoma, 14:213 in CML, 15:119 Centromere amplified sequences in melanoma line, 14:131 heterochromatin in melanoma line, 14:131 premature separation in AML, 16:109

Subject Index

separation in bone marrow chromosomes, 16:109 Cervical cancer chromosome aberration in lymphocytes of patients, 17:347 endomitoses in, 16:1 mitotic abnormalities in, 16:1 NOR in cells of patients with precancerous and cancerous lesions, 18:275 SCE in lymphocytes of patients, 14:67 X°chromatin in, 16:1 t(1;5), 16:269 Chemicals and chromosome changes, 14:37 1-methyl-3-nitro-l-nitrosoquanidine (MNNG) and chromosome changes, 14:37 Chrondrosarcoma myxoid, chromosome changes, 14:219 t(9;22) in, 14:219 Choriocarcinoma chromosome polymorphism in cell lines, 16:251 karyotypes of cell lines, 16:251 Chromosomal diagnosis of polyposis coli and Gardner's syndrome, 15:321 methods in hematologic disorders, 18:1 radiosensitivity in A-T, 14:163 Chromosome damage in patients with multiple cancers, 17:35 markers in large bowel cancer, 16:229 nomenclature, 14:1 Philadelphia, 14:1 #1 and #7 in hematologic disorders, 18:189, 193, 199, 207 #1 in ALL, 15:303 #1 in bladder cancer, 15:253 #1 in CML, 14:23 #1 in endometrial cancer, 18:283 #1 in ovarian cancer, 16:65 #1 in ovarian tumor, 14:147 #1 polymorphism, 14:31 #1 polymorphism of C-bands in cancer and myeloproliferative patients, 18:325 #1 in rhabdomyosarcoma, 16:189 #1 in seminoma, 17:315 #1 in Wilms' tumor, 14:95,331 #2 and #8 in Burkitt's lymphoma, 16:283 #3 in bladder cancer, 15:253 #3 in ovarian cancer, 16:65 #3 in prolymphocytic leukemia, 14:191 #3 in rhabdomyosarcoma, 16:189 #3 in Wilms' tumor, 14:95

Subject Index

3p in lung cancer cell line, 15:335; 16:175 # 4 , # 1 1 , and #17 in m y e l o d y s p l a s t i c syndrome, 18:265 # 5 in a d u l t T-cell leukemia, 15:65 #5 in APL, 14:247 # 5 in k i d n e y cancer, 14:197 5 q - in hematologic disorders, 17:189 # 6 in Burkitt's l y m p h o m a , 15:159 # 6 in cancer, 18:183 # 6 in malignant melanoma, 16:179 # 6 in ovarian cancer, 16:65 # 6 in ovarian tumor, 14:147 # 6 in teratocarcinoma, 15:99 6 q - in cancer, 18:183 # 7 and # 8 in Ph-negative chronic eosinophilic leukemia, 17:159 # 7 in AML, 14:77 # 7 in carcinoid lung tumor, 15:277 # 7 in gamma heavy chain disease, 15:1 # 7 in Ph-negative CML, 14:179 # 7 in W i l m s ' tumor, 14:95 # 8 in AML, 14:45, 77 # 8 in APL, 14:247 # 8 in CML, 14:111 # 9 in AML, 18:105 # 9 in CML, 14:61,183 # 9 in T-cell line (human), 14:89 # 9 in W i l m s ' tumor, 14:31, 95 9q34 in CML, 17:367 # 1 0 in ANLL, 16:361 # 1 0 in W i l m s ' tumor, 14:95 #11 in b l a d d e r cancer, 15:253; 16:289 #11 in i n d u c e d Syrian hamster cell line, 18:131 #11 in preleukemia, 14:119 #11 in teratocarcinoma, 15:99 #11 in W i l m s ' tumor, 14:23; 14:95; 14:331; 15:79 1 1 q - in sideroblastic anemia, 16:275 #12 in CML, 14:61 #12 in p r e l e u k e m i a and leukemia, 15:95 #12 in seminoma, 17:315 12p in hematologic disorders, 15:309 iso12p in testicular tumors, 15:375 #13 in hematologic disorders, 18:235; 18:243 13q14 in hematologic disorders, 18:247 13q14 in retinoblastoma, 16:321 - 1 3 in glioblastoma cell line, 17:257 #13 in k i d n e y cancer, 14:197 #14 in l y m p h o m a , 14:205 #14 in W i l m s ' tumor, 14:95 1 4 q l l in adult T-cell leukemia, 17:279 14q + in Haitian with AIDS and Burkitt's l y m p h o m a , 17:283 14q+ in l y m p h o m a , 17:325

365

1 4 q - in HCL, 16:91 #15 in m e l a n o m a line, 14:131 #16 in AML (noninvolvement), 17:1 #16 in ANLL, 14:185,371; 17:1, 17, 359; 18:351 # 1 6 in DMS, 14:371; 17:1 # 1 6 in T-cell line, 14:31 #17 in ALL, 14:45 #17 in APL, 14:247 #17 in b l a d d e r cancer, 15:253 #17 in ovarian cancer, 16:65 iso(17) in ALL, 14:45 iso(17) in APL, 14:247 iso(17) in Ph-negative CML, 14:323 #19 in p r e l e u k e m i a and leukemia, 15:95 #20 in AML, 14:77 #20 and c-src locus, 18:223 #21 in APL, 14:247 #21 in W i l m s ' tumor, 14:45, 77 #22 in CML, 14:23, 61; 15:89 X chromosomes in ovarian tumors, 14:147 X in AML, 15:137 - Y in AML, 17:269 Chromosome changes or aberrations chemically induced, 14:37 in acute monoblastic leukemia, 16:95 in acute T-cell leukemia, 15:181 in adult T-cell leukemia, 15:65; 17:279 in ALL, 15:47,303; 16:21; 17:165 in AML, 14:73; 18:105 in APL, 14:247 in Burkitt's l y m p h o m a , 14:339; 16:283, 341 in b l a d d e r cancer, 15:253 in blast crisis of CML, 16:235 in breast cancer, 16:49 in chondrosarcoma, 14:219 in choriocarcinoma cell lines, 16:251 in CLL, 15:227; 16:103; 18:307 in CML, 14:111,179,313; 15:17, 199; 16:235; 18:65 in CMML, 15:273 in endometrial cancer, 18:283 in erythroleukemia, 17:143 in Ewing's sarcoma, 15:215 in fibroblasts of patients with colon and rectum adenomatosis, 17:333 in glioblastoma cell line, 18:141 in Hodgkin's disease, 16:123 in h u m a n T-cell line, 14:89 in k i d n e y cancer, 14:197 in leukemic cells of patients with constitutional anomalies, 16:207 in l y m p h o c y t e s of colon cancer patients, 14:235

366 Chromosome changes--cont'd. in lymphocytes of patients with cervical cancer, 17:347 in lymphocytes of patients with polyposis coli, 17:355 in lymphoid cell lines, 14:205 in male breast cancer, 15:113 in male homosexuals, 18:337 in mouse lymphoma, 14:303 in myelodysplastic disorders, 15:153 in myelodysplastic syndromes, 16:157 in ovarian tumors, 14:147, 153; 16:65 in preleukemia, 14:119 in prison-acquired lymphoproliferative syndrome, 15:7 m prolymphocytic leukemia, 14:191 m prostate cancer, 16:301 m rat epithelial cells, 14:37 m retinoblastoma cell lines, 17:95 m rhabdomyosarcoma, 14:175; 16:189 m secondary lymphoma, 17:29 m seminoma, 17:315 m Sezary's syndrome, 16:117 m testicular tumors, 15:375 m Waldenstrom's macroglobulinemia, 18:155 in Wilms' tumor, 14:95,331 5 q - in blast crisis of CML, 16:365 5 q - in CMML, 15:269 5 q - in hematologic disorders, 17:189 Chronic granulocytic leukemia (CGL): See Chronic myelocytic leukemia Chronic lymphocytic leukemia (CLL) AA, AN, and NN classification of, 18:307 abnormal/normal metaphase ratio, 18:307 cell cycle of lymphocytes, 17:181 chromosome changes, 15:227; 16:103 fluorescent bodies in lymphocytes, 15:227 mitogens used, 17:181 prognosis in, 18:307 Chronic myelocytic leukemia (CML) activity of NOR, 16:311 blast crisis, 14:111,293; 15:17; 16:235, 365; 17:13; 18:65 c-abl translocation in "masked" Ph, 18:95 cell kinetics in, 14:111 cellular markers, 15:119 chromosome #9, 14:179 chronic phase, 14:227; 15:17; 18:65 complex Ph in, 14:23, 61,313; 15:89; 16:305; 18:215 cytogenetic studies in, 14:111,281,293, 313; 15:17; 16:235; 18:65

Subject Index

differential between Ph ÷ ALL and blast crisis of P h ÷ CML, 18:49 distinct cell lines in blast crisis, 17:21 effects of therapy, 18:65 efficacy of various cytogenetic methods, 18:1 eosinophilic, 17:159 extramedullary tumors, 15:119 in family with Robertsonian, t(14:15), 18:229 iso(17) in Ph-negative CML, 14:323 karyotype of cell lines K562, 17:55; 18:27 karyotypic evolution, 14:111; 15:17; 18:65 lymphoid crisis, 16:235 methods for chromosome analysis, 18:1 multistep pathogenesis, 14:111 near-triploidy in blast crisis, 18:113 NOR of bone marrow cells, 16:311 optimal leukocyte concentration for metaphase yield, 17:75 Ph-negative, 14:179, 323 Ph-negative and del(7), 14:179 Philadelphia chromosome in, 14:3, 61, 313; 15:17, 89; 16:305; 17:365; 18:65, 215 predictive parameters, 14:227,293; 18:65 role of, 9q34, 17:367 rRNA genes in K562 cell line, 18:27 SCE in, 14:111 SCE in lymphocytes of patients, 15:169 splenectomy and chromosome changes, 14:227 trisomy 7 and 8 in Ph-negative, 17:159 value in prediction of acute phase, 14:293 variant Ph chromosomes, 14:3, 23, 61, 313, 15:89, 199; 16:305; 17:365; 18:95, 215 5 q - , 17:189 5 q - in blast crisis, 16:365 Chronic myelogenous leukemia; see Chronic myelocytic leukemia Chronic myeloid leukemia; see Chronic myelocytic leukemia (CML) Chronic myelomonocytic leukemia (CMML) chromosomes in, 14:281; 15:273 5 q - in, 15:269 Chronic prolymphocytic leukemia; see Prolymphocytic leukemia Clonal evolution, in acute monoblastic leukemia, 16:95 Colon cancer in cotton-top tamarins, 14:83

Subject Index

C-bands in patients, 14:235 C-bands in patients with adenomatosis of colon and rectum, 18:31 chromosomal diagnosis of polyposis, 15:321 chromosome changes in effusions, 16:33 chromosome changes in lymphocytes of patients with polyposis coli, 17:355 c-myb and SCE in cell line, 18:251 colorectal cancer in a Navajo family, 15:209 cytogenetic and cytokinetic studies in patients with adenomatosis, 16:73 familial in tamarins?, 14:83 hereditary adenomatosis, 16:73 increased chromosome aberrations in fibroblasts of patients with adenomatosis, 17:333 karyotype of cancer cell line (COLO 205), 18:251 marker chromosomes; 16:229 Colony forming cells (CFU-S) erythroid (BFU-E) in Ph + ALL, 18:49 in AML, 14:267 SCE in CFU-S of AML, 14:267 Congenital acute monocytic leukemia with t(X;10), 16:357 t(13;14) and osteosarcoma, 17:123 Constitutional chromosome anomalies cytogenetic findings in leukemic cells, 16:207 leukemia in, 16:207 trisomy 21, 16:207 t(13;14), 16:207 t(14;15) and CML, 18:229 t(Y;17), 16:207 XXY, 16:207 XYY, 16:207 Y q - , 16:207 Culture of bone marrow vs. other methods for chromosome analysis in hematologic disorders, 18:1 Cytogenetics; see also Karyotype and Chromosome changes in acute T-cell leukemia, 15:181 in adult T-cell leukemia, 15:65; 17:279 in ALL, 15:47, 303; 16:21; 17:165 in AML, 18:105 in bladder cancer, 15:253 in blast crisis of CML, 16:235 in Burkitt's lymphoma, 14:33a; 16:283; 16:341 in choriocarcinoma cell lines, 16:251 in CLL, 15:227; 16:103; 18:307 in CMML, 15:273 in endometrial cancer, 18:283

367 in in in in

erythroleukemia, 17:143 glioblastoma cell line, 18:141 Hodgkin's disease, 16:123 leukemic cells of patients with constitutional changes, 16:207 in lymphoma cell lines, 14:205 in male breast cancer, 15:113 in male homosexuals, 18:337 in myelodysplastic disorder, 15:153; 16:157 m prolymphocytic leukemia, 14:191 m prostate cancer, 16:307 m retinoblastoma cell lines, 17:95 m rhabdomyosarcoma, 14:175; 16:189 m secondary lymphoma, 17:29 m seminoma, 17:315 m Sezary's syndrome, 16:117 m T-cell lymphoma, 14:257 m Waldenstrom's macroglobulinemia, 18:155 of acute monoblastic leukemia, 16:95 of APL, 14:247 of chondrosarcoma, 14:219 of CML, 14:111,179, 183: 15:17; 18:65, 215 of embryonal rhabdomyosarcoma, 14:175 of Ewing's sarcoma, 15:215 of kidney cancer, 14:197 of mouse lymphoma, 14:303 of ovarian tumor, 14:147, 153; 15:199; 16:65 of testicular tumors, 15:375 5 q - , 17:189 Cytogenetic, studies in patients with colorectal adenomas, 15:73 Deletion 3p in prolymphocytic leukemia, 14:191 5p in adult T-cell leukemia, 15:65 11p in aniridia-Wilms' tumor, 15:79 12p in preleukemia and leukemia, 15:95 5q in CMML, 15:269 5q in secondary leukemia (eosinophilic), 16:81 14q in hairy cell leukemia, 16:91 5 q - in hematologic disorders, 17:189 6 q - in cancer, 18:183 1 3 q - in hematologic disorders, 18:235, 243 Dicentric chromosomes, their origin in Bloom's syndrome, 15:293 symmetric and asymmetric chromosomes, 15:293

368 Dihydrofolate reductase, gene amplification in methotrexateresistant human cell line, 17:289 DNA, amplification in retinoblastoma, 17:95 Double minute chromosomes in ANLL, 18:333 in HeLa cell line, 18:43 in rhabdomyosarcoma, 16:189 in prematurely condensed chromatin of tumors, 16:145 in tumors, 16:145 Down's syndrome ALL in, 15:109 chromosome changes in leukemic cells, 16:207 lymphocyte proliferation, 15:109 SCE in lymphocytes, 15:109 Dysmyelopoietic syndromes (DMS) chromosome #16, 14:371 cytogenetic evolution, 16:157 efficacy of cytogenetic methods, 18:1 following Alkeran therapy, 15:95 hypotetraploidy in, 18:179 leukemia, eosinophilia, and chromosome changes, 14:371 methods of chromosome analysis, 18:1 preleukemia with t(2p;11q), 15:143 t(1;7) in, 18:189, 193, 199, 207 t(3;16) in, 14:371 5 q - , 17:189 Effusion ascitic in ovarian cancer, 14:153; 16:65 chromosome changes in cancer, 16:33, 145 double minute chromosomes in tumors, 16:145 pleural in CML, 14:111 prematurely condensed chromatin in tumors, 16:145 Electron microscopy; see also Ultrastructure in cytogenetics, 15:349 of chromosomes, 15:349 scanning, of marker chromosome, 15:177 Endometrial cancer, chromosome #1 in, 18:283 Endomitoses, in cervical cancer, 16:1 Eosinophilia anomaly of #16 in ANLL, 17:359 and chromosome #16, 14:371; 17:359 in ANLL and inv(16), 14:185; 17:359 Eosinophilic, chronic leukemia with trisomy 7 and 8, 7:159 Erythroleukemia cell line (K562), 18:159

Subject Index Friend virus induced, 16:199 genes encoding for et and 13globulin, 18:159 hypotetraploid, 18:179 karyotype in murine, 16:199 karyotypes, 18:159 major karyotypic abnormalities, 17:143 near-tetraploid, 17:143; 18:179 t(7;11),t(16;17) in, 18:159 Esterase-D, phenotypes in retinoblastoma patients, 16:321 Ewing's sarcoma biological characterization (growth, tumorigenicity, ct-adrenergic receptors) 15:215 chromosome changes, 15:215 t(1;16), 15:215 t(11;22), 15:215; 17:87 Familial colorectal cancer in Navajo family, 15:209 Po}yposis coli, 15:321; 16:73 von Hippel-Landau disease, 16:3 t(13;14) and osteosarcoma, 17:123 Fibroblasts ataxia-telangectasia, 14:163 C-banding in patients with adenomatosis of colon and rectum, 18:31 increased chromosome aberrations in patients with colon and rectum cancer, 17:333 mutagen effects in patients with colon and rectum adenomatosis, 17:333 radiosensitivity in A-T, 14:163 Fragile sites chromosomal and cancer, 14:369; 17:1; 18:81 in patients with malignancies, 17:10; 18:81 noninvolvement of site on #16 in AML, 17:1 site of 16q22 in AML, 17:1 Gardner's syndrome chromosomal diagnosis, 15:321 cytogenetic and cytokinetic studies, 16:73 G-banding, method for leukemic metaphases, 15:373 Gene amplification of dihydrofolate reductase in human cell line, 17:189 of rRNA in K562 cell line, 18:27 Genes encoding for c~- and [3-globin in erythroleukemia, 18:159

Subject Index involved in chromosome translocations, 18:159 Glioblastoma cell lines with near-haploidy, 18:141 cell line with - 13, 17:257 glial fibrillary acid protein (GFAP) in, 18:141 Globins, e~ and ~ in erythroleukemia cells, 18:159 Hairy cell leukemia (HCL) cell cycle of stimulated B-cell leukemic lymphocytes, 17:181 cytogenetic studies in stimulated lymphocytes, 17:69 1 4 q - in, 16:91 - 2 2 in, 17:69 Heavy chain disease, trisomy 7 in, 15:1 HeLa cell line, double minutes in, 18:43 Hematologic disorders; see also Myelodysplastic syndromes and Dysmyelopoeitic disorders and Preleukemia chromosome 12p involvement, 15:309 efficacy of various cytogenetic methods, 18:1 methods of bone marrow chromosome analysis, 18:1 t(1;7) in, 18:189, 193, 199, 207 Hepatoblastoma cytogenetic analysis, 15:369 t(4;19), 15:369 Hepatoma cell line, karyotype, 18:11 hepatitis B integration site in cell line, 18:19 Hereditary adenomatosis of colorectum, 15:321; 16:73 colorectal cancer in Navajo family, 15:209 cytogenetic and cytokinetic studies in patients with adenomatosis of colorectum, 16:73 Heterochromatin C-bands in colon cancer patients, 14:235 centromeric, amplified in melanoma line, 14:235 in cancer patients, 18:325 in choriocarcinoma cell lines, 16:251 in patients with CNS tumors, 15:129 in patients with myeloproliferative disorders, 18:325 in preleukemia, 14:31 in chromosomes #1, #6, and #9 in children with malignant disease, 16:169

369 of fibroblasts in cases with adenomatosis of colon and rectum, 18:31 of lymphocytes in breast cancer patients, 18:37 polymorphism, 14:31; 18:325 polymorphism in neoplasia, 14:31; 18:325 role of variation in instability of marker chromosome in tumor progression, 15:283 variants in neoplasia, 14:31; 18:325 Heteromorphism; see Polymorphism High resolution, of chromosomes in hematologic cells, 14:275 Histocompatibility, antigen in hybrids of mouse neuroblastoma and rat glioma or liver cells, 16:219 Hodgkin's disease cytogenetic findings, 16:123 immunoblastic lymphoma following Hodgkin's disease, 18:55 immunologic findings, 16:123 Homogeneously staining regions (HSR) amplified sequences in, 14:131 in melanoma, 14:131 in retinoblastoma cell lines, 17:95 NOR and centromeric sequences in, 14:131 proposed designation, 18:353 Homosexuals, chromosome aberrations in males, 18:337 Hybrids between mouse neuroblastoma and rat glioma or liver cells, 16:219 karyotypes of, 16,219 Hyperdiploidy, in dermal cultures in pancreatic cancer, 14:285 Hyperplasia, parathyroid and two-hit theory of neoplasia, 14:175 Hypodiploidy in ALL, 16:137 in ANLL, with DMS, 18:333 Hypotetraploid in DMS, 18:179 in hematologic disorders, 18:179 Immunoblastic lymphoma following Hodgkin's disease, 18:55 t(8;14) in tumor cells and t(7;14) in lymphocytes, 18:55 Immunoglobulins and T-lymphocytes of A-T, 18:159 heavy chain disease, 15:1 Hodgkin's disease, 16:123 in B cells of A-T, 18:159 )t gene in Ph-positive ALL, 18:173 Isochromosome X in AML, 15:137

370 Isochromosome--cont'd.

12p in testicular tumors, 15:375 #17 in ALL, 14:45 #17 in Ph-negative CML, 14:323; 15:17

Karyotype changes in AML, 14:73; 18:105 colon cancer cell line (COLO 205), 18:251 evolution in acute monoblastic leukemia, 16:95 evolution in ALL, 15:61 evolution in CML, 14:111 evolution in myeloma, 17:301 in acute monoblastic leukemia, 16:95 in acute T-cell leukemia, 15:181 in adult T-cell leukemia, 15:65, 17:279 in ALL, 15:47, 303; 16:21; 17:165 in APL, 14:247 in bladder cancer, 15,253 in blast crisis of CML, 16:235 in Burkitt's lymphoma, 14:339; 16:283, 341 in chondrosarcoma, 14:219 m choriocarcinoma cell line, 16:251 in CLL, 15:227; 16:103, 18:307 in CML, 15:17, 199: 16:235; 18:65,215 m CMML, 15:273 m erythroleukemia, 17:143 m endometrial cancer, 18:283 m glioblastoma cell line, 18:141 In Hodgkin's disease, 16:123 m kidney cancer, 14:197 in leukemic cells of patients with constitutional changes, 16:207 in lymphoma cell lines, 14:205 in male breast cancer, 15:113 in mouse erythroleukemia (virus induced), 16:199 in myelodysplastic disorders, 15:153; 16:157 in ovarian cancer, 14:153; 16:65 in prostate cancer, 16:301 in retinoblastoma cell lines, 17:95 in rhabdomyosarcoma, 14:175; 16:189 in secondary lymphoma, 17:29 in seminoma, 17:315 in Sezary's syndrome, 16:117 in testicular tumors, 15:375 in Waldenstrom's macroglobulinemia, 18:155 of Ewing's sarcoma, 15:215 of human T-cell line, 14:89 of mouse neuroblastoma and rat glioma or liver cells, 16:219 progression in Syrian hamster cell line, 18:131

Subject Index variation in mouse lymphoma, 14:303 5 q - in hematologic disorders, 17:189 Kidney cancer, 14:197 transitional cell cancer of pelvis, 14:197 Wilms' tumor, 14:95 t(5;14) in kidney cancer, 14:197 Klinefelter's syndrome chromosome changes in leukemic cells, 16:207 Large bowel cancer; see also Colon and Rectum direct chromosome preparation, 16:229 marker chromosomes, 16:229 Large cell cancer, lung, cell line karyotype, 15:335 Leukemia myeloid, in mouse, 14:125 prolymphocytic, 14:191 5 q - in, 17:189 Leukocyte, concentration of leukemic leukocytes and optimal metaphase yield, 17:75 Linkage study in MEN type IIa, 15:315 in Sipple's syndrome, 15:315 Liver tumors; see Hepatoblastoma Lung cancer cell lines, 15:335 carcinoid tumor, 15:277 chromosome changes in effusions, 16:33 karyotypes, 15:335; 16:33 trisomy 7 in carcinoid, 15:277 3 p - in small cell cancers, 16:175 Lymphoblastic, T-cell line, karyotype, 14:89 Lymphocytes aberrations in patients with cervical cancer, 17:347 and origin of malignant myeloma, 17:13 C-bands in breast cancer patients, 18:37 C-bands in colon cancer patients, 14:235 C-bands in normal subjects, 18:31, 37 C-bands in patients with cancer or myeloproliferative disorder, 18:325 C-bands in patients with CNS tumors, 15:129 cell cycle of B-cell leukemias, 17:181 chromosome aberrations in male homosexuals, 18:337 chromosome changes in colon cancer patients, 14:235 chromosome studies in polyposis coli, 17:355 cytogenetic and cytokinetic studies in patients with adenomas of colon, 16:73

Subject Index differential susceptibility to mutagens in cancer and normal subjects, 17:307 fluorescent bodies in CLL, 15:227 heterochromatin in neoplasia, 14:31 NOR in patients with precancerous and cancerous lesions of cervix, 18:275 proliferation in Down's syndrome, 15:109 radiation sensitivity in Bloom's syndrome, 16:131 SCE in a case of Down's syndrome and ALL, 15:109 SCE in myelodysplastic disorder, 15:151 SCE in patients with ANLL, AML, or CML, 15:169 SCE in patients with multiple cancers, 17:35 t(7;14) in case with immunoblastic lymphoma, 18:55 Lymphoma Burkitt's, 14:339; 15:159; 16:283 cell lines, 14:205 chromosome changes in secondary, 17:29 chromosomes #2 and #8 in Burkitt's, 16:283 cytogenetic changes in Hodgkin's disease, 16:123 cytogenetic studies in, 14:205,257; 17:29 diffuse mixed cell, 14:257 histiocytic, 14:205 immunoblastic with t(8;14),t(7;14) in lymphocytes of a case with immunoblastic lymphoma, 18:55 immunologic studies in, 14:205 mouse (thymic), 14:303 mycosis fungoides, 18:295 secondary, 17:29 Sezary's syndrome, 16:117 T-cell, 14:257,266; 16:117 XYY and mycosis fungoides, 18:295 t(14;18) in, 14:257 6 q - in Burkitt's. 15:159 14q÷, AIDS, and Burkitt's in Haitians, 17:283 14q÷ change, 17:325 Lymphoproliferative disorders efficacy of various bone marrow cytogenetic methods, 18:1 heavy chain disease, 15:1 methods for bone marrow chromosomes, 18:1 prison acquired, chromosome changes, 15:7 t(10;19), 17:185 5 q - in, 17:189

3 71 Marker chromosomes in large bowel cancer, 16:229 chromosomes in ovarian cancer, 16:65 chromosomes in rat epithelial line, 15:283 heterochromatin and chromosome instability, 15:283 5 q - in hematologic disorders, 17:189 "Masked" Ph, c-abl translocation in, 18:95 Mediastinal; see also Teratocarcinoma, teratocarcinoma, 15:99 Melanoma chromosome changes in line, 14:131 chromosome #6, 16:179 chromosome #15 in cell line, 14:131 cytogenetic finding in brain melanoma, 15:179 human cell line (HeWo), 14:131 SCE and cell proliferation in patients with malignant, 15:37 Mesothelioma, familial, 15:25 Metaphase, optimal yield and leukemic leukocyte concentration, 17:75 Metastatic, prostate cancer, 16:301 Methods chromosome banding, 14:275 chromosomes in bladder cancer, 16:259 direct vs. culture in hematologic disorders, 18:1 double staining of Q-bands and SCE, 16:153 G-banding in leukemic cells, 15:393 high resolution, 14:275 metaphase yield and leukocyte concentration, 17:75 methotrexate synchronization, 14:275 of bone marrow chromosome analysis, 18:1 optimal leukocyte concentration for chromosome analysis in leukemia, 17:75 Q-banding and SCE, 16:153 SCE, using anti°BrdU antibody, 15:187 silver staining of NOR, 16:311 thymidine release, 14:275 Methotrexate, synchronization method, 14:275 Mitogens, in B-cell leukemia lymphocytes, 17:181 Mitosis, abnormalities in cervical cancer, 16:1 Monosomy of X in ovarian tumor, 14:147 #7 in AML, 14:77 #20 in AML, 14:77 #21 in AML, 14:77

372 Mouse erythroleukemia, virus induced, 16:199 glioblastoma hybrid with rat glioma or liver cells, 16:219 myeloid leukemia, 14:125 RSV transfused line, 15:283 SCE in myeloid leukemia cells, 14:125 thymic lymphoma, 14:303 Multiple endocrine neoplasia (MEN}, linkage study in type IIa, 15:315 Mutagen differential effect on lymphocytes of cancer and normal subjects, 17:307 effects on fibroblasts of patients with colon and rectum cancer, 17:333 Mycosis fungoides chromosome changes in, 18:295 in an XYY male, 18,295 Myelodysplastic syndromes: See also Dysmyelopoietic disorders and Preleukemia chromosome changes in, 15:153; 16:157 chromosome changes in CMML, 15:273 chromosomes #4, #11, and #17, 18:265 efficacy of various bone marrow cytogenetic methods, 18:1 in multiple myeloma, 16:81 insertion of part of #5 into #1, 16:353 karyotypic evolution, 16:157 methods for bone marrow chromosome analysis, 18:1 SCE in bone marrow cells, 15:151 sideroblatic anemia with 1 1 q - , 16:275 t(1;7) in, 18:189, 193,199, 207 5 q - in, 17:189 5 q - in CMML, 15:269 Myelofibrosis; see also Myeloproliferative disorders 12p in, 15:309 5 q - in, 15:189 1 3 q - , 18:235,243 Myeloma cytogenetic changes, 17:13, 301 eosinophilic leukemia in, 16:81 karyotypic evolution, 17:301 precursor lymphocytes, 17:13 Myeloproliferative disease (MPD) chromosomes in, 14:275 chromosome #16, 14:371 efficacy of various cytogenetic methods, 18:1 karyotypic evolution, 16:157 methods of bone marrow cytogenetic analysis, 18:1 SCE in bone marrow cells, 15:151 t(1;7) in, 18:189,193,199, 207 #1 polymorphism in patients, 18:325

Subject Index 12p in myelofibrosis, 15:309 5 q - , 17:189 1 3 q - , 18:235,243 Near-haploid, human glioblastoma cell line, 18:141 Near-tetraploidy in acute leukemia, 14:45 in ALL, 14:45 in AML, 14:45 Near-triploidy in blast crisis of Ph+ CML, 18:113 in Ph+ ALL, 18:113 Nervous system tumors, C-banding in patients with, 15:129 Neurofibromatosis, non-neural malignancy complicating, 18:87 Nomenclature, for HSR, proposed, 18:353 Nondisjunction of chromosomes, #11 in chemically induced Syrian hamster cell line, 18:131 Nucleolar, changes in hepatocarcinoma, 17:151 Nucleolar organizer regions {NOR) activity in CML marrow, 16:311 amplified sequences, 14:131 in cells of CML, 16:311 in human melanoma line, 14:131 in bone marrow cells, 16:311 in patients with precancerous and cancerous lesions of cervix, 18:275 rRNA in K562 cell line, 18:27 silver staining, 16:311 Nude mice, growth of human glioblastoma cells in, 18:145 Oncogenes amplified c-myb in colon cancer cell line, 18:251 and human cancer, 14:347 c-abl translocation in "masked" Ph, 18:95 c-Ha-ras 1 in aniridia-Wilms' tumor deletion of 11p, 15:79 chromosome #6 and c-myb, 18:251 c-myb and chromosome #6, 18:183 c-myb in mediastinal teratocarcinoma, 15:99 c-ras, 14:191 c-src in chromosome #20, 18:123 mobility in a human leukemia line, 17:133 possible involvement in neoplasia, 18:159 Osteosarcoma, in a family with Robertsonian t(13;14), 17:123

Subject Index

Ovarian cancer, effusions, 16:33 chromosome changes in tumor, 14:147, 153; 16:33 clonal variants in cancer, 14:153 common marker chromosomes in cancer, 16:65 granulosa cell tumor, 114:147 3 p - in cancer, 16:65 Pancreas cancer of, 14:285; 16:33 chromosome changes in effusion, 16:33 heterogeneity in cancer of, 14:285 Philadelphia chromosome (Ph) ALL with near-triploidy, 18:113 break interrupts k gene in ALL, 18:173 breakpoint at 22qll in ALL, 18:173 c-abl translocation in "masked" Ph, 18:95 complex, 14:23, 61,313, 215 due to interstitial deletion, 14:3 in ALL, 14:11; 18:173 in CML, 14:11; 15:17 "masked" Ph in CML, 18:95 new mechanism, 14:3 nomenclature, 14:1 role of 9q34, 17:367 T-cell ALL, 16:297 variant in ALL, 14:3, 11, 61,313 variant in CML, 14:1, 23, 61,313; 15:89, 199; 16:305; 18:95,215 #9 in variant Ph translocation, 14:183 t(2:9:22), 16:305, 18:215 t(3;9;22), 18:215 t(5;9;22), 16:305 t(6;9;22) in CML, 15:199 t(6;22), 14:313 t(7;8;9;22), 16:305 t(7;22) in CML, 15:199; 16:305 t(8;9;22), 16:305 t(8;12;9;22), 14:313 t(8;22), 16:305 17:365 t(9;11;22) in CML, 14:313; 15:199; 16:305 t(9;12;22), 18:215 t(9;13;22), 16:305 t(9;15;22), 14:11 t(9;17;22), 16:305 ins(11;22), 14:3 t(12;22) and (9;12), 14:61 t(13;22) in CML, 15:199 t(13;17;22), 18:215 t(14;22), 14:11 t(15:17:22), 16:305 t(16;22), 18:215 t(17;22), 18:215 2 2 q - , 18:215

3 73 Philadelphia-negative CML, deletion of #7, 14:179 Phytohemagglutinin (PHA) stimulated lymphocytes in adult T-cell leukemia, 15:65 stimulated lymphocytes in male homosexuals, 18:337 Plasma cell leukemia, hypotetraploid, 18:179 Polymorphism C-bands in colon cancer patients, 14:235 C-bands in patients with CNS tumors, 15:129 chromosomal in choriocarcinoma cell lines, 16:251 heterochromatin, 14:31; 18:325 in neoplasia, 14:31; 18:325 in preleukemic states, 14:31; 18:325 of C-bands in cancer and myeloproliferative disorder patients, 18:325 of C-bands in lymphocytes of breast cancer patients, 18:37 of chromosomes #1, #9, and #16 in children with malignant diseases, 16:169 of fibroblasts in cases with adenomatosis of colon and rectum, 18:31 Polyposis coli, chromosomal diagnosis, 15:321 coli, chromosome studies in familial form, 17:355 cytogenetic and rectum, hereditary, 16:73 Polycythemia vera 5 q - in, 17:189 1 3 q - , 18:235 Preleukemia chromosome #11 in, 14:119 dysmyelopoietic with t(2p;11q), 15:143 following Alkeran therapy, 15:95 pancytopenia changing to AML and #16, 17:1 polymorphism in, 14:31 SCE in bone marrow of myelodysplastic disorder, 15:151 #16 (noninvolvement), 17:1 t(1;7) in 18:189, 193, 199, 207 19q+ in, 15;95 1 2 p - in, 15:95 5 q - in, 17:183 1 3 q - in, 18:235, 243 Premature centromere separation; see Centromere Prolymphocytic leukemia cell cycle of lymphocytes, 17:181 chromosomes in, 14:275 c-ras oncogene in, 14:191

374 Prolymphocytic leukemia--cont'd. del(3p) in, 14:191 Prostate, chromosome changes in metastatic cancer, 16:301 Protooncogenes; see Oncogenes Q-bands, simultaneous detection with SCE, 16:153 Radiation, sensitivity of Bloom's syndrome lymphocytes, 16:131 Rat chromosomes in epithelial cells of digestive tract, 14:37 glioma or liver cells hybrids with mouse neuroblastoma, 16:217 Rectum cancer proness, 14:235 C-bands in patients with adenomatosis of colon and rectum, 18:31 C-bands in patients with cancer of, 14:235 cytogenetic and cytokinetic studies in patients with adenomatosis, 16:73 increased chromosome aberrations in fibroblasts of patients, 17:333 Refractory anemia chromosome #11 in, 14:119 polymorphism in, 14:31 5 q - in, 17:189 1 1 q - in sideroblastic anemia terminating in leukemia, 16:275 Renal cancer; see Kidney Retinoblastoma chromosomes in cell lines, 17:95 cytogenetic forms, 16:321 DNA amplification, 17:95 esterase-D phenotypes, 16:321 SCE in cells of patients, 16:321 survey in 66 patients, 16:321 translocations, 16:332 13q14 in, 16:321 Rhabdomyosarcoma chromosome changes in, 14:169; 16:189 embryonal, 14:169 Ring chromosome, in glioblastoma cell line, 18:141 RNA rRNA gene activity in hemin-induced K562 cells, 17:113 rRNA in K562 (CML) cell line, 18:27 Robertsonian translocation, t(14;15) and CML, 18:229 Sarcoma chromosome changes, 14:219 Ewing's chromosomes, 15:215; 17:87

Subject Index myxoid chondrosarcoma, 14:219 osteosarcoma and familial t(13;19), 17:123 rhabdomyosarcoma, 14:169; 16:189 Secondary leukemia acute eosinophilic in multiple myeloma, 16:81 chromosomes in, 14:281 t(1;7), relation to, 18:189, 193, 199, 207 12p in leukemia in Hodgkin's disease, 15:309 5 q - in, 17:189 Seminoma, chromosome analysis, 17:315 Sex and age in AML, 14:73 and karyotype in AML, 14:73 Sex-chromatin, in cervical cancer, 16:1 Sezary's syndrome, cytogenetic findings, 16:117 Sideroblastic anemia insertion of part of #5 into #1, 16:353 leukemia in, 16:275 polymorphism in, 14:31 5 q - in, 17:189 1 1 q - in, 16:275 1 3 q - in, 18:235 Sipple's syndrome, linkage studies in, 15:315 Sister chromatid differentiation, unusual due to differences in BrdU incorporation, 15:85 Sister chromatid exchange (SCE) double staining technique, 16:153 in adult T-cell leukemia, 15:65 in cells of patients with malignant melanoma, 15:37 in CML, 14:11, 15:169 in CFU-S of AML, 14:267 in colon cancer cell line, 18:251 induced in lymphocytes, 14:67 inhibition by cycloheximide in Bloom's syndrome, 17:43 in lymphocytes, 14:67; 15:169; 17:35 in lymphocytes of patients with ALL and Down's syndrome, 15:109 in lymphocytes of patients with ANLL, ALL, and CML, 15:169 in mouse myeloid leukemia, 14:125 in myelodysplastic bone marrows, 15:151 in patients with cervical cancer, 14:67 in patients with hereditary adenomatosis of colon, 16:73 in patients with multiple cancers, 17:35 in rat epithelial cell line, 15:243 in retinoblastoma patients, 16:321 method using anti-BrdU antibodies, 15:187

Subject Index simultaneous detection with Q-bands, 16:153 spontaneous levels in lymphocytes, 14:67; 15:169 Small cell cancer, of lung, cell line karyotypes, 15:335 Somatic cell hybrids, with aniridiaWilms' tumor 1 1 p - cells, 15:79 Somatic crossing over in Bloom's syndrome erythrocytes, 15:237 in normal ceils, 15:237 Splenectomy chromosomes and CML, 14:227 predictive parameters, 14:227 Squamous cell carcinoma, lung, cell line karyotype, 15:335 Stomach, cancer, chromosome changes in effusions, 16:33 Synchronization, method vs. others in bone marrow cytogenetic analysis, 18:1 T-cell adult leukemia, 15:65 ALL with Ph, 16:297 interleukin 2-dependent line from patient with mycosis fungoides, 18:295 involvement in CML, 15:119 line (CCRF-CEM) karyotype, 14:89 lymphoma, diffuse mixed, 14:257 lymphoproliferative disorders with t(10;19), 17:185 partial expression in Burkitt's ALL in AIDS, 16:341 Sezary's syndrome, 16:117 t(11;19) in child with acute leukemia, 15:181 14qll in adult T-cell leukemia, 17:279 Techniques; see Methods Teratocarcinoma c-myb in, 15:99 mediastinal, chromosome changes in, 15:99 metastatic, identical changes in, 15:99 Testicular tumors iso12p changes, 15:375 seminoma, chromosomes, 17:315 Thrombocythemia; see also Thrombocytosis, essential, chromosome changes, 18:91 Thrombocytosis; see also Thrombocythemia chromosome changes in thrombocythemia, 18:91 5 q - in essential, 17:189

3 75 Transitional cell carcinoma of bladder, 15:253 of kidney pelvis, 14:197 t(5;14) in, 14:197 Translocations complex in APL, 14:247; 16:45 chromosome regions of differential activity and translocation, 18:159 dir ins(11;22)(q13;qllq13), 14:3 in ALL, 15:50 in Burkitt's lymphoma, t(8;14), and t(2;8), 14:339, 16:341 in Ewing's sarcoma, 15:215 in mediastinal teratocarcinoma, 15:99 involving #3 in bladder cancer, 15:253 involving #17 in bladder cancer, 15:253 in retinoblastoma, 16:332 novel 4 q l l q in ALL, 16:245 of c-abl in "masked" Ph, 18:95 Philadelphia chromosome in T-cell ALL, 16:297 role of 9q34 in CML, 17:367 specific, 18:159 variant in CML, 15:89, 199 t(1;1) in ovarian cancer, 16:65 t(1;3) in ovarian cancer, 16:65 t(1;5) in cervical cancer, 16:269 t(1;6) in Ewing's sarcoma, 15:215 t(1;6) in ovarian cancer, 16:65 t(1;6) and t(10;19) in secondary lymphoma, 17:29 t(1;7) in hematologic disorders, 18:189, 193, 199, 207 t(1;8) in APL, 16:349 t(1;16) in endometrial cancer, 18:283 t(1;19) in ALL, 17:79 t(2p;11q) in preleukemia, 15:143 t(2;9;22) in CML, 16:305; 18:215 t(2;11) in acute monoblastic leukemia, 16:95 t(2;14) in B-cells of A-T, 18:159 t(2;14) in CLL, 18:307 t(2;22) in CML, 15:199; 16:305 t(3;5) in AML, 16:279 t(3;9;22) in CML, 18:215 t(3;17) in ovarian cancer, 16:65 t(4;11) in acute leukemia, 16:21,245 t(4;11) in MDS, 18:265 t(4;19) in hepatoblastoma, 15:369 t(4;11;17) in ALL, 17:81 t(5;9;22) in CML, 16:305 t(5;14) in kidney cancer, 14:197 t(6;6;11) in teratocarcinoma, 15:99 t(6;8) in ALL, 18:105 t(6;9) in ANLL, 18:303 t(6;9;22) in CML, 15:199 t(6;17) in erythroleukemia, 18:159 t(6;22) in CML, 14:313

376 Translocations--cont' d. t(7;8;9;22) in CML, 16:305 t(7;9) in CML, 18:215 t(7;11) in erythroleukemia, 18:159 t(7;14) in CLL, 18:307 t(7;14) in lymphocytes of case with immunoblastic lymphoma, 18:55 t(8;9;22) in CML, 16:305 t(8;12;9;22) in CML, 14:313 t(8;14) in CLL, 18:307 t(8;14) in immunoblastic lymphoma, 18:55 t(8;14) in Waldenstrom's macroglobulinemia, 18:155 t(8;17) in APL, 17:61 t(8;21) in AML, 14:45; 18:105 t(8;21;15) in AML, 15:191 t(8;22) in CML, 16:305; 17:365 t(9;11;27) in CML, 14:313; 15:199; 16:305 t(9;12;22) in CML, 18:215 t(9;13) in pancytopenia advancing to AML, 17:1 t(9;13;22) in CML, 16:305 t(9;15;22)(q12;q26;q11), 14:11 t(9;17) in CML, 18:215 t(9;17;22) in CML, 16:305 t(9;21) in adult T-cell leukemia, 15:65 t(9;22) in chondrosarcoma, 14:219 t(10;19) in ALL, 16:369 t(10;19) in lymphoproliferative disorder, 17:185 t(11;13) in erythroleukemic cell line (K562), 18:159 t(11;14) in CLL, 18:307 t(11;17) in AMoL, 17:83 t(11;17) in MDS, 18:265 t(11;19) in acute T-cell leukemia, 15:181 t(11;22) in Ewing's sarcoma, 15:215; 18:87 t(12;22) in (9;12), 14:61 t(13;13) in CLL, 18:307 t(13;14) (Robertsonian) in osteosarcoma, 17:123 t(13;17;22) in CML, 18:215 t(14;14) in A-T, 18:159 t(14;15) (Robertsonian) and CML, 18:229 t(14;18) in T-cell lymphoma, 14:257; 16:341 t(14;22)(q32;q11) in CML, 14:11 t(15;17) in APL, 14:247; 18:315 t(15;17) in K562 cell line, 18:27 t(15;17;22) in CML, 16:305 t(16;22) in CML, 18:215 t(17;22) in CML, 15:199; 18:215 t(X;10) in acute monocytic leukemia, 16:357

Subject Index t(X;15;17) in APL, 16:45 t(Y;9) in CLL, 18:307 Trisomy chromosome changes in leukemic cells of patients with constitutional translocations, 16:207 constitutional, 16:207 #7 in heavy chain disease, 15:1 #7 in lung carcinoid tumor, 15:227 #8 in AML, 14;77 #8 in CML, 14:111 #11 in preleukemia, 14:119 #20 in AML, 14:77 #21 in AML, 14:77 Tumor colony-forming units (TCFU), in ovarian cancer, 14:153 Tumorigenicity, hybrids of mouse neuroblastoma and rat glioma or liver cells, 16:219 Tumors and chromosome #6, 18:183 carcinoid of lung, 15:277 CNS, 15:129 double minute chromosomes, 16:145 in Turner's syndrome, 16:335 of large bowel, 16:229 ovarian, 14:147, 153 prematurely condensed chromatin, 16:145 testicular, 15:375 Wilms', 14:95,331 5 q - in, 17:189 6 q - in, 18:183 Turner's syndrome multiple cancers in, 16:335 45X/46,XXp - / 4 6 ,XX/47,XXX, 16: 335 Two-hit theory of neoplasia, pathogenesis of hyperparathyroidism, 14:175 Ultrastructural aspects of cytogenetics, 15:349 studies in APL and chromosome changes, 14:247 studies of chromosomes, 15:349 studies of marker chromosomes, 15:177 Uterine cancer; see Endometrial cancer and Cervical cancer Variant chromosome #9 and variant Ph, 14:183 clones in ovarian cancer, 14:153 heterochromatin, 14:31 Ph chromosome, 14:3, 11, 23, 61,183 Virus hepatitis B integration site in a hepatoma cell line, 18:19

Subject Index Friend, induced erythroleukemia in mouse, 16:199 von Hippel-Landau disease cancer genes in, 16:13 multiple cancers, 16:13 Waldenstrom's macroglobulinemia + 3, + 18, - 21 in, 18:155 t(8;14) in, 18:155 Wilms' tumor chromosome #1, 14:331 chromosome #11 in, 14:95, 331 chromosomes #1, #3, #7, #9, #10, and #14, 14:95 cytogenetic study of, 14:95,331 localization of c-Ha-ras 1 outside the del(11p), 15:79 X-chromatin, in cervical cancer, 16:1 X chromosome change in leukemic cells of XXY patients, 16:207

377 change in ovarian tumor, 14:147 isochromosome X in AML, 15:137 t(X;10) in acute monocytic leukemia, 16:357 t(X;15;17) in APL, 16:45 X-ray, chromosomal sensitivity in A-T, 14:163 XXY male, chromosome changes in leukemic cells in, 16:207 XYY male, chromosome changes in leukemic cells in, 16:207 Y chromosome chromosome changes in leukemic cells of patients with XYY, 16:207 chromosome changes in leukemic cells of patients with Y q - , 16:207 loss in AML, 17:269 loss in APL, 18:319 loss in CML, 14:313; 15:17 mycosis fungoides in XYY male, 18:295 t(Y;9) in CLL, 18:307